Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Monitored congressional efforts around the SACKLER Act.
Duration: November 1, 2007
to
present
General Issues: Health Issues , Bankruptcy , Medicare/Medicaid , Pharmacy , Budget/Appropriations
Spending: about $2,629,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Brian Sutter Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11
Leg Asst.Rep Camp, Feb '03-May'08;
Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Asst July'0
David Stratton Edwards Staff Assistant for Rep. John Sullivan Nov. '03-Aug.'06
Legislative Counsel for Rep. Tom Cole August '10-March '15
Staff Assistant for Rep. John Sullivan Nov.'03-Aug. '06
Legislative Counsel for Rep. Tom Cole Aug.'10-March '15
Staff Assistant for Rep. John Sullivan Nov. '03- Aug. '06
Legislative Counsel for Rep. Tom Cole Aug. '10- March '15
Tom Wharton Health Legislative Assistant - Senator Joe Lieberman. May 2011 - June 2012
Senior Legislative Assistant - Congressman Dan Boren. July 2008 - June 2011
Chris Bowlin Sen. McCain-Hlth&Domestic Policy Advisor
2009-Aug 2013; Dept. of HHS-Deputy Asst Secret
for Legislation 2008-2009; Dept of Labor- Deputy
Asst. Secretary for Congressional and Intergovt
Affairs 2001-2002; Professional Staff- House
Education and Workforce Committee 1999-2001
Amy Shank 2005-2011 Senate HELP Cmte; Dir. of Oversight
2003-2004 Senate Budget Committee
2001-2002 Ofc. of Asst. GOP Leader Don Nickles
2003-2004 Budget Committee
2005-2011 Senate HELP Cmte; Dir of Oversight
2001-2002 Ofrc. of Asst. GOP Leader Don Nickles
Emily Wilkinson Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
Emily Holland Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
Christopher Davis Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011.
Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011)
David Jory n/a
Bill Brewster n/a
Bill K. Brewster n/a
David Thompson n/a
Rick Shelby n/a
Steve Irizarry n/a
Brian Munroe n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 21.
Original Filing: 301568803.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 19.
Original Filing: 301532267.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 23, 2023.
Original Filing: 301517180.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301486330.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301468214.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301437901.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act, including H.R. 2096 / S. 2472 and HR 4777 / S 2497, including outreach regarding potential committee activity on the legislation.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415687.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act, including H.R. 2096 / S. 2472 and HR 4777 / S 2497, including outreach regarding potential committee activity on the legislation.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of PURDUE PHARMA, LLP in Q32022 on Oct. 20, 2022.
Original Filing: 301418830.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act, including H.R. 2096 / S. 2472 and HR 4777 / S 2497, including outreach regarding potential committee activity on the legislation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301393458.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act, including H.R. 2096 / S. 2472 and HR 4777 / S 2497, including outreach regarding potential committee activity on the legislation.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301364857.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act, including H.R. 2096 / S. 2472 and HR 4777 / S 2497, including outreach regarding potential committee activity on the legislation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 21, 2022.
Original Filing: 301339306.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act, including H.R. 2096 / S. 2472 and HR 4777 / S 2497, including outreach regarding potential committee activity on the legislation.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301777.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored congressional efforts around the SACKLER Act, including H.R. 2096 / S. 2472 and HR 4777 / S 2497, including outreach regarding potential committee activity on the legislation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 16, 2021.
Original Filing: 301278044.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301260629.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240379.xml
Lobbying Issues
Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222797.xml
Lobbying Issues
Monitoring for issues related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 21, 2020.
Original Filing: 301203219.xml
Lobbying Issues
Monitoring for issues related to prevention of abuse, misuse or diversion of prescription drugs; federal response to the COVID-19 crisis; prescription drug payment reform; and pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301170672.xml
Lobbying Issues
Monitoring for issues related prevention of abuse, misuse or diversion of prescription drugs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301126422.xml
Lobbying Issues
Monitoring for issues related prevention of abuse, misuse or diversion of prescription drugs.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 17, 2019.
Original Filing: 301067898.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act.Issues related to legal settlements.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates, abuse deterrent formulations.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301055811.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act.Issues related to legal settlements.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates, abuse deterrent formulations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 19, 2019.
Original Filing: 301031567.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates, abuse deterrent formulations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 20, 2019.
Original Filing: 301011090.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates, abuse deterrent formulations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 11, 2018.
Original Filing: 300984270.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300977716.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300951566.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934859.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 19, 2017.
Original Filing: 300909996.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300895810.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300877273.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 20, 2017.
Original Filing: 300853066.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837776.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300820238.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 15, 2016.
Original Filing: 300791850.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781936.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300762964.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 15, 2015.
Original Filing: 300735322.xml
Lobbying Issues
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on April 16, 2015.
Original Filing: 300717666.xml
Lobbying Issues
issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
issues related to Labor-HHS funding
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Jan. 16, 2015.
Original Filing: 300699151.xml
Lobbying Issues
general health issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; issues relating to prescription drug abuse; Canada compliance issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R.486)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680831.xml
Lobbying Issues
General health issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; issues relating to prescription drug abuse; Canada compliance issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $50,000. The report was filed on July 8, 2014.
Original Filing: 300654254.xml
Lobbying Issues
General health issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; issues relating to prescription drug abuse; Canada compliance issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $40,000. The report was filed on April 15, 2014.
Original Filing: 300636432.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety. Issues relating to prescription drug abuse.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $35,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616806.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $35,000. The report was filed on Oct. 16, 2013.
Original Filing: 300595282.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $31,500. The report was filed on July 10, 2013.
Original Filing: 300570253.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $47,000. The report was filed on April 17, 2013.
Original Filing: 300551739.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act
Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $15,750. The report was filed on Jan. 16, 2013.
Original Filing: 300530059.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Prescription and Generic Drug User Fee legislation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)
Stop Tampering of Prescription Pills Act of 2012 (H.R. 6160)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $15,750. The report was filed on Oct. 10, 2012.
Original Filing: 300504968.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Prescription and Generic Drug User Fee legislation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $32,000. The report was filed on July 12, 2012.
Original Filing: 300483156.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Prescription and Generic Drug User Fee legislation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $32,000. The report was filed on April 12, 2012.
Original Filing: 300459670.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $45,000. The report was filed on Jan. 17, 2012.
Original Filing: 300438831.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Oct. 13, 2011.
Original Filing: 300413076.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on July 19, 2011.
Original Filing: 300394764.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on April 19, 2011.
Original Filing: 300370222.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Jan. 20, 2011.
Original Filing: 300349229.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Oct. 14, 2010.
Original Filing: 300313180.xml
Lobbying Issues
General health care issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Food and Drug Administration Amendments Act of 2007 (P.L. 110-85); Stop Oxy Abuse Act (H.R. 4956)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on July 14, 2010.
Original Filing: 300286844.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85); Stop Oxy Abuse Act (H.R.4956)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on April 19, 2010.
Original Filing: 300266866.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Jan. 14, 2010.
Original Filing: 300231077.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (H.R. 3200); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Oct. 6, 2009.
Original Filing: 300201166.xml
Lobbying Issues
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
general Medicare and Medicaid issues, including but not limited to, coverage and reimbursement; America's Affordable Health Choices Act of 2009 (HR3200); America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on July 14, 2009.
Original Filing: 300176674.xml
Lobbying Issues
general healthcare issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; Food and Drug Administration Amendments Act of 2007 (Public Law No. 110-85)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on April 15, 2009.
Original Filing: 300148460.xml
Lobbying Issues
General healthcare issues related to pharmaceuticall and biological products; Federal Food, Drug and Cosmetic Act (21USC 9); Drug Safety; Food and Drug Administration Amendments Act of 2007 (Public Law No.l10-85); FDA Globalization Act (HR 759)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Jan. 13, 2009.
Original Filing: 300116340.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9);
Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Oct. 17, 2008.
Original Filing: 300097347.xml
Lobbying Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9);
Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Controlled Drug Substances Act (21 USC 13)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on July 9, 2008.
Original Filing: 300062147.xml
Lobbying Issues
General Healthcare Issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Pharmaceutical issues, including but not limited to: The Federal Food, Drug, and Cosmetic Act; The Controlled Drug Substances Act; Drug Imporation; and Drug Safety
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on April 16, 2008.
Original Filing: 300038854.xml
Lobbying Issues
General Healthcare Issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
general pharmaceutical issues, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Controlled Drug Substances Act; drug imporation; and drug safety
Agencies Lobbied
U.S. House of Representatives
0th Quarter, 2007
In MM, CAPITOL HILL CONSULTING GROUP lobbied for PURDUE PHARMA, LLP , earning $20,000. The report was filed on Aug. 1, 2007.
Original Filing: 200043621.xml
Lobbying Issues
General healthcare issues
Lobbying Issues
General pharmaceutical related issues
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...